EU-approved Keytruda
Phase 3
EU-approved Keytruda is one of 8 therapeutic programs targeting Non-Squamous Non-Small Cell Lung Cancer. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
7
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
7 competitors in Non-Squamous Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Paraplatin
AAvyxa
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Alimta
GGynecologic Oncology Group
Phase 3
Rilvegostomig
AstraZenecaPhase 3
Xalkori
PPrism Pharmaceuticals
Phase 2
CT-P51
CCelltrion
Phase 3
EU-approved Keytruda
CCelltrion
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Squamous Non-Small Cell Lung Cancer1 trial
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for EU-approved Keytruda. EMBL-EBI & Wellcome Sanger Institute.
- [3]